New immunotherapy combo shows promise for stubborn lymphoma
NCT ID NCT07480850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients achieve complete disappearance of their cancer for at least four weeks. Researchers will also track overall survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab (a type of immunotherapy) combined with gemcitabine and oxaliplatin (chemotherapy drugs)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat lymphoma that hasn't responded to initial therapy.
- What could go wrong
- This is a small, early-phase study with only 40 participants and no comparison group, so results may not apply broadly. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.